Besides, there is an ongoing phase II clinical trial (NCT02091960) (Table 2) evaluating the efficacy of enzalutamide combined with trastuzumab in HER2/AR-positive locally advanced or metastatic BC. The gene discussed is AR; the disease is breast cancer.